Print Page  Close Window
Meridian Bioscience H. Pylori Patent Upheld by European Patent Office

CINCINNATI--(BUSINESS WIRE)--Oct. 18, 2005--Meridian Bioscience, Inc., (NASDAQ:VIVO) today announced that its patent entitled "Immunoassay for Helicobacter pylori in Fecal Specimens" has been confirmed as valid by the European Patent Office. The validity of the Patent had been challenged in four Oppositions filed by a total of seven parties. The objections raised were that the Patent added subject matter to the Application as originally filed, lacked novelty, lacked inventive steps and was insufficiently disclosed.

At the end of Oral Proceedings on October 11, 2005, following a three-year written procedure, the European Patent Office Opposition Division decided the Patent should be maintained as granted, and that all the Oppositions had failed.

Jack Kraeutler, President and COO, stated, "Helicobacter pylori, which infects nearly 50% of the world's population, is recognized as the number one cause of peptic ulcers and has also been classified as a serious carcinogen. Through the use of Meridian's two patented rapid tests, Premier Platinum HpSA(R) and ImmunoCard STAT!(R) HpSA, clinicians around the world can rapidly diagnose the presence of this pathogen and follow-up with a prescription for treatment. The validation of our patent by the EPO is a strong endorsement of our unique technology."

Meridian holds additional patents in the United States and other markets around the world for H. pylori technology.

Meridian is a fully integrated life science company that manufactures, markets and distributes a broad range of innovative diagnostic test kits, purified reagents and related products and offers biopharmaceutical enabling technologies. Utilizing a variety of methods, these products provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as gastrointestinal, viral, and respiratory infections. Meridian diagnostic products are used outside of the human body and require little or no special equipment. The Company's products are designed to enhance patient well-being while reducing the total outcome costs of healthcare. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections, serology, parasitology and fungal disease diagnosis. In addition, Meridian is a supplier of rare reagents and specialty biologicals along with proteins and other biologicals used by biopharmaceutical companies engaged in research for new drugs and vaccines. The Company markets its products to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices and diagnostics manufacturers in more than 60 countries around the world. The Company's shares are traded through Nasdaq's National Market, symbol VIVO. Meridian's website address is

CONTACT: Meridian Bioscience, Inc., Cincinnati
John A. Kraeutler, 513-271-3700

SOURCE: Meridian Bioscience, Inc.